S&P 500   3,930.23 (-3.88%)
DOW   31,511.38 (-3.50%)
QQQ   290.46 (-5.13%)
AAPL   140.50 (-5.86%)
MSFT   253.99 (-4.81%)
FB   192.72 (-4.89%)
GOOGL   2,247.74 (-3.51%)
AMZN   2,130.00 (-7.69%)
TSLA   703.47 (-7.63%)
NVDA   169.20 (-6.92%)
BABA   87.16 (-5.25%)
NIO   15.69 (-5.65%)
AMD   95.93 (-6.38%)
CGC   5.57 (-5.43%)
MU   70.83 (-4.90%)
T   20.15 (-2.04%)
GE   75.06 (-1.75%)
F   12.73 (-5.91%)
DIS   104.26 (-4.03%)
AMC   12.66 (-1.86%)
PFE   50.18 (-2.26%)
PYPL   76.86 (-3.62%)
NFLX   176.60 (-7.33%)
S&P 500   3,930.23 (-3.88%)
DOW   31,511.38 (-3.50%)
QQQ   290.46 (-5.13%)
AAPL   140.50 (-5.86%)
MSFT   253.99 (-4.81%)
FB   192.72 (-4.89%)
GOOGL   2,247.74 (-3.51%)
AMZN   2,130.00 (-7.69%)
TSLA   703.47 (-7.63%)
NVDA   169.20 (-6.92%)
BABA   87.16 (-5.25%)
NIO   15.69 (-5.65%)
AMD   95.93 (-6.38%)
CGC   5.57 (-5.43%)
MU   70.83 (-4.90%)
T   20.15 (-2.04%)
GE   75.06 (-1.75%)
F   12.73 (-5.91%)
DIS   104.26 (-4.03%)
AMC   12.66 (-1.86%)
PFE   50.18 (-2.26%)
PYPL   76.86 (-3.62%)
NFLX   176.60 (-7.33%)
S&P 500   3,930.23 (-3.88%)
DOW   31,511.38 (-3.50%)
QQQ   290.46 (-5.13%)
AAPL   140.50 (-5.86%)
MSFT   253.99 (-4.81%)
FB   192.72 (-4.89%)
GOOGL   2,247.74 (-3.51%)
AMZN   2,130.00 (-7.69%)
TSLA   703.47 (-7.63%)
NVDA   169.20 (-6.92%)
BABA   87.16 (-5.25%)
NIO   15.69 (-5.65%)
AMD   95.93 (-6.38%)
CGC   5.57 (-5.43%)
MU   70.83 (-4.90%)
T   20.15 (-2.04%)
GE   75.06 (-1.75%)
F   12.73 (-5.91%)
DIS   104.26 (-4.03%)
AMC   12.66 (-1.86%)
PFE   50.18 (-2.26%)
PYPL   76.86 (-3.62%)
NFLX   176.60 (-7.33%)
S&P 500   3,930.23 (-3.88%)
DOW   31,511.38 (-3.50%)
QQQ   290.46 (-5.13%)
AAPL   140.50 (-5.86%)
MSFT   253.99 (-4.81%)
FB   192.72 (-4.89%)
GOOGL   2,247.74 (-3.51%)
AMZN   2,130.00 (-7.69%)
TSLA   703.47 (-7.63%)
NVDA   169.20 (-6.92%)
BABA   87.16 (-5.25%)
NIO   15.69 (-5.65%)
AMD   95.93 (-6.38%)
CGC   5.57 (-5.43%)
MU   70.83 (-4.90%)
T   20.15 (-2.04%)
GE   75.06 (-1.75%)
F   12.73 (-5.91%)
DIS   104.26 (-4.03%)
AMC   12.66 (-1.86%)
PFE   50.18 (-2.26%)
PYPL   76.86 (-3.62%)
NFLX   176.60 (-7.33%)
OTCMKTS:PVCT

Provectus Biopharmaceuticals (PVCT) Stock Forecast, Price & News

$0.06
0.00 (-2.63%)
(As of 05/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.05
$0.06
50-Day Range
$0.05
$0.07
52-Week Range
$0.04
$0.08
Volume
122,480 shs
Average Volume
242,429 shs
Market Capitalization
$24.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.14
30 days | 90 days | 365 days | Advanced Chart
Receive PVCT News and Ratings via Email

Sign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Provectus Biopharmaceuticals logo

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.

Headlines

AtScale Named Snowflake Premier Partner
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PVCT
Previous Symbol
NYSEMKT:PVCT
Employees
2
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
($0.01) per share

Profitability

Net Income
$-5.54 million
Pretax Margin
-2,612.40%

Debt

Price-To-Earnings

Miscellaneous

Free Float
400,152,000
Market Cap
$24.87 million
Optionable
Not Optionable

Company Calendar

Today
5/18/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Provectus Biopharmaceuticals (OTCMKTS:PVCT) Frequently Asked Questions

Are investors shorting Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 200 shares, an increase of 100.0% from the April 15th total of 100 shares. Based on an average daily trading volume, of 622,700 shares, the days-to-cover ratio is presently 0.0 days.
View Provectus Biopharmaceuticals' Short Interest
.

Who are Provectus Biopharmaceuticals' key executives?
Provectus Biopharmaceuticals' management team includes the following people:
  • Dr. Eric A. Wachter, Co-Founder & CTO (Age 59, Pay $230.86k)
  • Ms. Heather Raines CPA, Chief Financial Officer (Age 55, Pay $115.5k)
  • Mr. Bruce Horowitz, COO & Director (Age 66, Pay $329.4k)
What other stocks do shareholders of Provectus Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Provectus Biopharmaceuticals investors own include Vertex Energy (VTNR), Good Times Restaurants (GTIM), Merck & Co., Inc. (MRK), Oncolytics Biotech (ONC), Cytori Therapeutics (CYTX), (DARA) (DARA), Energy Transfer (ET), Gilead Sciences (GILD), iShares Biotechnology ETF (IBB) and MaxLinear (MXL).

What is Provectus Biopharmaceuticals' stock symbol?

Provectus Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "PVCT."

How do I buy shares of Provectus Biopharmaceuticals?

Shares of PVCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Provectus Biopharmaceuticals' stock price today?

One share of PVCT stock can currently be purchased for approximately $0.06.

How much money does Provectus Biopharmaceuticals make?

Provectus Biopharmaceuticals has a market capitalization of $24.87 million. The company earns $-5.54 million in net income (profit) each year or ($0.01) on an earnings per share basis.

How many employees does Provectus Biopharmaceuticals have?

Provectus Biopharmaceuticals employs 2 workers across the globe.

What is Provectus Biopharmaceuticals' official website?

The official website for Provectus Biopharmaceuticals is www.provectusbio.com.

How can I contact Provectus Biopharmaceuticals?

Provectus Biopharmaceuticals' mailing address is 10025 INVESTMENT DRIVE SUITE 250, KNOXVILLE TN, 37932. The company can be reached via phone at (866) 594-5999, via email at [email protected], or via fax at 866-998-0005.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.